

PAR/CS/NSE/2021-22/51

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Date: 16/11/2021**Symbol - PAR, ISIN: INE04LG01015**

Subject: Investors Presentation

Ref.: Regulation 30 read with Schedule III of SEBI (Listing Obligations And
Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to above captioned subject and pursuant Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby attached our latest Investors Presentation.

You are requested to kindly take note on your record.

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED

(Mr. Falgun V. Savani)**Managing Director****DIN: 00198203**

Encl: Investor Presentation



H1/Q2-FY22 Earnings Presentation

Company Overview




Company Overview



- Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development and manufacturing of APIs.



- The Company today manufactures more than 28 different products and all the requisite grades as available in the market. The product portfolio presently comprises of 18 APIs and 10 Fine Chemicals which are marketed domestically and exported.
- Currently, the company owns and operates a manufacturing facility at Bhavnagar in Gujarat with an annual capacity of 9,700 MT.
- The company is the largest manufacturer of Magnesium Hydroxide, Sucralfate and Magnesium Trisilicate in India.
- Company's key customers include Essential Drugs Company Ltd., Pfizer Ltd., United Phosphorus Ltd., Cipla Ltd., etc.
- PDCL exports its products to approximately 16 countries, including Germany, the United Kingdom, Bangladesh, Iran, and U.A.E etc.
- APIs, also known as "bulk drugs" or "bulk actives" are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.

Operational Revenues (INR Mn)



Business Mix (H1-FY22)

International Sales





Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 18 APIs and 10 Fine Chemicals which are marketed domestically and exported.



Global Presence: The Company is operating both in domestic and export markets. The export products are to approximately 16 countries, including Germany, United Kingdom, Bangladesh, Iran, and U.A.E, Indonesia, Japan, South Korea, etc.



Experienced Promoters: Led by qualified and experienced Promoters and key managerial personnel, who we believe have extensive knowledge and understanding of the APIs business environment and have the expertise and vision to organically scale up the business.



Robust Chemistry Capabilities: A research driven Company with R&D efforts focused on developing processes and achieving process improvements and production cost efficiencies.



Diversified Customer base: Catering to more than 191 customers through dealers/agents worldwide.



Established Sales and distribution network: Comprising of more than 40 dealers and distribution network is spread globally comprising of 13 agents.



Cash Rich Company: The company is a net debt free and generates free cash flow. They plan its expansions through internal accruals.

The background of the slide is a blurred image of a financial report. It features a bar chart with blue bars and numerical values, a pie chart with segments in shades of blue and grey, and a pair of black-rimmed glasses resting on the top right. Two overlapping circles, one dark blue and one yellow, are positioned on the left side of the slide.

FINANCIAL & OPERATIONAL HIGHLIGHTS

H1/Q2-FY22 Financial & Operational Highlights

Q2-FY22 Financial Highlights


Revenue INR 196 Mn	EBITDA INR 40 Mn	EBITDA Margin 20.41%
PAT INR 22 Mn	PAT Margin 11.22%	Diluted EPS INR 1.8

H1-FY22 Financial Highlights

Revenue INR 361 Mn	EBITDA INR 82 Mn	EBITDA Margin 22.71%
PAT INR 47 Mn	PAT Margin 13.02%	Diluted EPS INR 3.8

Operational Highlights

- Since the beginning of the financial year we are facing the Price Rise of Indonesian Coal. The same we were not able to pass it on the customer immediately.
- We have been experiencing the Price Hike in Major Raw Materials like Caustic Soda Lye, Soda Ash and Sodium Silicate during the second quarter but it was not significant till end of August hence we were not passing it to the customer. But as it has significantly move upwards we have started to revise the prices by mid-September.
- On the export front the company has experienced the sudden increase in Sea Freight and there were commitments to several Overseas Customers which has to be fulfilled and hence the margins came lower during the first and second quarters.
- Company has already started passing on the prices for both domestic and export clients gradually.



A background image featuring a pair of black-rimmed glasses resting on a document with various financial charts. A large blue circle on the left contains the title text. A yellow circle is positioned above the blue one. The background includes a bar chart with monthly data from February to November, a pie chart with segments labeled 29 and 22, and a line graph showing a downward trend with a value of -1.15. The overall theme is financial analysis and reporting.

H1/Q2-FY22 Financial Overview

Q2-FY22 Income Statement (IND-AS)

Income Statement (INR Mn)	Q2-FY22	Q2-FY21	Y-o-Y	Q1-FY22	Q-o-Q
Income from Operations	196	172	14.0%	165	18.8%
Total Expenses	156	121	28.9%	124	25.8%
EBITDA	40	51	(21.6)%	41	(2.4)%
<i>EBITDA Margin</i>	<i>20.41%</i>	<i>29.65%</i>	<i>(924) Bps</i>	<i>24.85%</i>	<i>(444) Bps</i>
Finance Cost	2	3	(33.3)%	-	NA
Depreciation	8	7	14.3%	8	NA
Other Income	-	-	NA	-	NA
Profit before Extra Ordinary Items	30	41	(26.8)%	33	(9.1)%
Extraordinary items	-	-	NA	-	NA
Profit Before Tax	30	41	(26.8)%	33	(9.1)%
Tax	8	6	33.3%	9	(11.1)%
Profit after tax	22	35	(37.1)%	24	(8.3)%
<i>PAT Margin</i>	<i>11.22%</i>	<i>20.35%</i>	<i>(913) Bps</i>	<i>14.55%</i>	<i>(333) Bps</i>
Other Comprehensive Income	-	-	NA	-	NA
Total Comprehensive Income	22	35	(37.1)%	24	(8.3)%
Diluted EPS (INR)	1.8	5.7	(68.4)%	2	(10.0)%

H1-FY22 Income statement (IND-AS)

Income Statement (INR Mn)	H1-FY22	H1-FY21	Y-o-Y
Income from Operations	361	283	27.6%
Total Expenses	279	205	36.1%
EBITDA	82	78	5.1%
<i>EBITDA Margin</i>	<i>22.71%</i>	<i>27.56%</i>	<i>(485) Bps</i>
Finance Cost	3	4	(25)%
Depreciation	17	15	6.7%
Other Income	1	1	NA
Profit before Extra Ordinary Items	63	60	5.0%
Extraordinary items	-	-	NA
Profit Before Tax	63	60	5.0%
Tax	16	9	77.8%
Profit after tax	47	51	(7.8)%
<i>PAT Margin</i>	<i>13.02%</i>	<i>18.02%</i>	<i>(500) Bps</i>
Other Comprehensive Income	-	-	NA
Total Comprehensive Income	47	51	(7.8)%
Diluted EPS (INR)	3.8	8.31	(54.3)%

Historical Income statement


Income Statement (INR Mn)	FY19	FY20	FY21	H1-FY22
Income from Operations	463	558	607	361
Total Expenses	381	464	448	279
EBITDA	82	94	159	82
<i>EBITDA Margin</i>	<i>17.71%</i>	<i>16.85%</i>	<i>26.19%</i>	<i>22.71%</i>
Finance Cost	20	8	6	3
Depreciation	30	27	28	17
Other Income	1	1	2	1
Profit before Extra Ordinary Items	33	60	127	63
Extraordinary items	-	-	(20)	-
Profit Before Tax	33	60	147	63
Tax	8	12	31	16
Profit after tax	25	48	116	47
<i>PAT Margin</i>	<i>5.40%</i>	<i>8.60%</i>	<i>19.11%</i>	<i>13.02%</i>
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	25	48	116	47
Diluted EPS (INR)	5.60	7.75	18.87	3.8

Balance Sheet


EQUITIES & LIABILITIES (INR Mn)	FY20	FY21	H1-FY22	ASSETS (INR Mn)	FY20	FY21	H1-FY22
Shareholder Funds	406	523	569	Non Current Assets	359	352	352
(A) Equity Share Capital	61	62	123	(A) Fixed Assets			
(B) Reserves & Surplus	345	461	446	(i) Tangible Assets	344	299	344
				(ii) Capital work-in-progress	7	45	-
Non-current Liabilities	87	82	78	(B) Non Current Investments	1	-	-
(A) Long Term borrowings	46	44	40	(C) Long Term Loans & Advances	7	8	8
(B) Deferred Tax Liabilities (net)	37	34	34				
(C) Long term Provisions	4	4	4				
Current Liabilities	108	159	89	Current Assets	242	412	384
(A) Short term borrowings	-	32	-	(A) Inventories	29	30	30
(B) Trade Payables	62	67	57	(B) Trade Receivables	124	125	141
(C) Other Current Liabilities	27	25	13	(C) Cash & cash equivalents	74	212	179
(D) Short term Provisions	19	35	19	(D) Short Term Loans & Advances	6	-	-
				(E) Other Current Assets	9	45	34
GRAND TOTAL - EQUITIES & LIABILITIES	601	764	736	GRAND TOTAL – ASSETS	601	764	736

Financial Highlights


Operational Revenue (INR Mn)




EBITDA (INR Mn) & EBITDA Margins (%)




PAT (INR Mn) & PAT Margins (%)




RoCE & RoE



Net Debt to Equity Ratio (x)




Net Worth (INR Mn)



Price Data (30th September, 2021)	INR
Face Value	10.0
Market Price	210.45
52 Week High/Low	210.45/49.00
Market Cap (Mn)	2,589.5
Equity Shares Outstanding (Mn)**	12.3
1 Year Avg Trading Volume ('000)	23.8

Shareholding Pattern as on 30th September, 2021



*** Issue of Bonus shares in the ratio of 1:1 on 30th April, 2021*

Par Drugs and Chemicals Limited:

The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from, this Presentation is expressly excluded. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care off in the presentation and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this presentation or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence, investigation etc may be done at your end. You may also contact us directly for any questions or clarifications at our end. This presentation contain certain statements of future expectations and other forward-looking statements, including those relating to our general business plans and strategy, our future financial condition and growth prospects, and future developments in our industry and our competitive and regulatory environment. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. In addition to statements which are forward looking by reason of context, the words 'may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue and similar expressions identify forward looking statements. Actual results, performances or events may differ materially from these forward-looking statements including the plans, objectives, expectations, estimates and intentions expressed in forward looking statements due to a number of factors, including without limitation future changes or developments in our business, our competitive environment, telecommunications technology and application, and political, economic, legal and social conditions in India. It is cautioned that the foregoing list is not exhaustive This presentation is not being used in connection with any invitation of an offer or an offer of securities and should not be used as a basis for any investment decision.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal
Valorem Advisors

Tel: +91-22-4903-9500

Email: pardrugs@valoremadvisors.com



Thank
You